Indivior

Indivior is a specialty pharmaceuticals business. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.

Indivior
TypePublic company
LSE: INDV
Industrypharmaceuticals
Founded1994
HeadquartersRichmond, Virginia
Key people
Howard Pien, Chairman
Shaun Thaxter, CEO
ProductsSubutex/Subuxone
Revenue$785 million (2019)[1]
$178 million (2019)[1]
$134 million (2019)[1]
Number of employees
796 (2019)[1]
Websitewww.indivior.com/

History

The company was established as the Buprenorphine division of Reckitt Benckiser in 1994.[2] In December 2014, Reckitt Benckiser spun off its specialty pharmaceuticals business into a separate company named Indivior.[3] By February 2015, the company was capitalised at £2.3 billion (US$3.1 billion) on the London Stock Exchange.[4]

In 2019, Indivior was indicted over claims that it had made false marketing claims about the effectiveness of its drug, Suboxone, and had concocted a scheme to direct patients towards doctors who were likely to prescribe Suboxone. Reckitt Benckiser has settled with the Justice Department to pay $1.4 billion to resolve a U.S. Federal investigation into sales and marketing of opioid addiction treatment.[5][6][7]

In July 2020, Indivior Solutions, Indivior Inc., and Indivior plc agreed to pay $600 million to resolve liability related to false marketing of Suboxone to MassHealth for use by patients with children under the age of six years old. Additionally, Indivior Solutions pled guilty to one-count of felony information.[8]

Operations

The company's main products are Subutex and its Naloxone-combined preparation Suboxone, both substitution products for opioid addiction.[2] Other products include remedies for cocaine and opioid analgesic overdose and treatment for alcohol dependence: the company claims this to be the largest pipeline of addiction drugs in the world.[9]

  • Suboxone sublingual film

References
  1. "Annual Report 2019" (PDF). Indivior. Retrieved 20 August 2020.
  2. "Indivior faces generic challenge". Investors Chronicle. 2 February 2015. Retrieved 22 March 2015.
  3. "RB complete demerger of Indivior - RB". RB. 23 December 2014. Archived from the original on 29 March 2015. Retrieved 21 March 2015.
  4. "Is Indivior PLC The Perfect Partner For AstraZeneca plc in Your Portfolio?". Retrieved 22 March 2015.
  5. Reuters (11 July 2019). "Reckitt to Pay $1.4 Billion to End Long-Running Indivior Probes". The New York Times. ISSN 0362-4331. Retrieved 11 July 2019.
  6. admin. "Reckitt to pay $1.4 billion to end long-running Indivior probes". Retrieved 11 July 2019.
  7. "Reckitt to pay $1.4 billion to end long-running Indivior probes". Reuters. 11 July 2019. Retrieved 11 July 2019.
  8. "Indivior Solutions Pleads Guilty to Felony Charge as Part of DOJ's Largest Opioid Resolution". uspsoig.gov. United States Postal Service Office of Inspector General. 24 July 2020. Archived from the original on 18 August 2020. Retrieved 7 September 2020. Indivior Solutions today pleaded guilty to a one-count felony information and, together with its parent companies Indivior Inc. and Indivior plc, agreed to pay a total of $600 million to resolve criminal and civil liability associated with the marketing of the opioid-addiction-treatment drug Suboxone. Together with a $1.4 billion resolution with Indivior’s former parent, Reckitt Benckiser Group PLC (RB Group), announced in 2019, and a plea agreement with Indivior plc’s former CEO, Shaun Thaxter, announced last month, the total resolution relating to the marketing of Suboxone is more than $2 billion – the largest-ever resolution in a case brought by the Department of Justice involving an opioid drug.
  9. "RB spin-out Indivior says addiction pipeline will deliver". Pharmaphorum. 21 November 2014. Retrieved 22 March 2015.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.